Investment Rating - The investment rating for the company is "Buy" [1] Core Insights - The company reported a revenue of 3.376 billion yuan, a net profit of 676 million yuan, and operating cash flow of 996 million yuan for FY2026H1, representing year-on-year growth of 7.0%, 11.9%, and 21.1% respectively. After excluding government subsidies, the net profit was 626 million yuan, reflecting a 15.5% increase year-on-year [2] - The company declared an interim dividend of 0.52 HKD per share, resulting in a dividend yield of 5.18% [2] - The company's brands showed varied performance, with JNBY, LESS, and emerging brands experiencing revenue growth of 5.7%, 16.3%, and 22.4% respectively, while the men's brand Su Xie continued to struggle [3] - The gross margin for FY2026H1 was 66.5%, an increase of 1.4 percentage points year-on-year, while the net profit margin rose to 20.0%, up 0.9 percentage points [4] - Inventory at the end of FY2026H1 was 1.02 billion yuan, a 9.4% increase year-on-year, with accounts receivable remaining stable at 220 million yuan [5] Financial Projections - Revenue forecasts for FY26-28 are 6.004 billion, 6.396 billion, and 6.806 billion yuan, with year-on-year growth rates of 8.21%, 6.53%, and 6.41% respectively. Net profit projections are 971 million, 1.040 billion, and 1.115 billion yuan, with growth rates of 8.72%, 7.08%, and 7.24% [6][8] - The estimated earnings per share (EPS) for FY26-28 are 1.86, 1.92, and 2.09 yuan, with corresponding price-to-earnings (PE) ratios of 9.4, 9.1, and 8.3 [6][8]

2026 年 2 月 27 日 公司研究 海内外市场开拓加速，25 年新签合同额稳步提升 ——中石化炼化工程（2386.HK）公告点评 要点 事件：公司发布公告，截至 2025 年 12 月 31 日止十二个月期间，公司新签订合 同总值为 1012.48 亿元，较截至 2024 年 12 月 31 日止十二个月期间的 1006.13 亿元增加 0.6%；于 2025 年 12 月 31 日，公司未完成合同量为 2038.50 亿元， 较 2024 年 12 月 31 日的 1726.76 亿元增加 18.1%。 点评： 新签合同额稳健增长，中石化集团内部合同额占比回升。2025 年，公司国内新 签合同 632 亿元，同比增长 2%，境外新签订合同 380 亿元，同比下降 1.3%， 海外合同占公司新签合同的 38%。2025Q4 单季，公司新签订合同总值为 99.01 亿元。分行业来看，25 年公司新签合同以炼油和石油化工为主，炼油、石油化 工、新型煤化工、储运及其他行业的新签合同额分别同比+77%、-3%、-34%、 -22%。分合同类型看，公司总承包合同持续增长，25 年工程总承包合同额为 735 亿元， ...

Investment Rating - The investment rating for Jiangnan Buyi (3306.HK) is "Buy" [1] Core Insights - The company reported a revenue of 3.376 billion yuan and a net profit of 676 million yuan for FY2026H1, representing a year-on-year growth of 7.0% and 11.9% respectively. After excluding government subsidies, the net profit increased by 15.5% to 626 million yuan [2] - The company declared an interim dividend of 0.52 HKD per share, resulting in a dividend yield of 5.18% [2] - The company's brands showed varied performance, with JNBY, LESS, and emerging brands experiencing growth, while the men's brand "Suxie" continued to face challenges [3] - The gross profit margin improved to 66.5%, up 1.4 percentage points year-on-year, while the net profit margin increased to 20.0%, up 0.9 percentage points [4] - Inventory at the end of FY2026H1 was 1.02 billion yuan, a 9.4% increase year-on-year, indicating growth in finished goods and raw materials [5] Financial Projections - Revenue forecasts for FY2026-2028 are 6.004 billion, 6.396 billion, and 6.806 billion yuan, with year-on-year growth rates of 8.21%, 6.53%, and 6.41% respectively. Net profit forecasts for the same period are 971 million, 1.040 billion, and 1.115 billion yuan, with growth rates of 8.72%, 7.08%, and 7.24% [6][8] - The estimated earnings per share (EPS) for FY2026-2028 are 1.86, 1.92, and 2.09 yuan, with corresponding price-to-earnings (PE) ratios of 9.4, 9.1, and 8.3 [6][8]

Investment Rating - The report maintains an "Outperform" rating for Galaxy Entertainment [2][6]. Core Insights - Galaxy Entertainment's Q4 2025 results met market expectations, with net revenue reaching HKD 13.83 billion, a year-on-year increase of 22.5%, and adjusted EBITDA of HKD 4.3 billion, up 32.7% year-on-year [3][12]. - The company's gaming revenue grew nearly 30% year-on-year, significantly contributing to overall revenue growth, with gaming and non-gaming segments contributing HKD 11.36 billion and HKD 1.74 billion, respectively [13][14]. - The VIP gaming segment showed strong growth, with gross gaming revenue (GGR) reaching HKD 13.95 billion, up 26.5% year-on-year, driven by higher win rates and increased betting amounts [14][15]. - The adjusted EBITDA margin improved to 31.1%, up 2.4 percentage points year-on-year, indicating enhanced operational efficiency [5][15]. - Market share increased to 21.8%, up from 20.2% in Q3 2025 and 19.8% in Q4 2024, reflecting the company's competitive positioning [16]. Financial Projections - The report forecasts net revenue for FY 2026 and 2027 to be HKD 52.48 billion and HKD 56.71 billion, respectively, with year-on-year growth rates of 6.6% and 8.1% [6][17]. - Gross gaming revenue is expected to reach HKD 52.70 billion and HKD 56.86 billion for FY 2026 and 2027, with growth rates of 7.2% and 7.9% [17]. - The adjusted EBITDA for FY 2026 and 2027 is projected to be HKD 15.07 billion and HKD 16.48 billion, with corresponding EBITDA margins of 28.7% and 29.1% [17].

Investment Rating - The report maintains a "Buy" rating for the company with a target price of HKD 74.14 [7][5]. Core Insights - The sale of UKPN will enhance cash reserves, supporting the company's global expansion and acquisition capabilities [1][3]. - The company is expected to experience a profit gap of approximately HKD 300 million annually if one-time gains are excluded from the sale [2]. - The company plans to utilize the proceeds from the sale for new investments or acquisitions and general working capital [3]. Financial Projections - The company forecasts net profits attributable to shareholders of HKD 61.6 billion, HKD 65.7 billion, and HKD 68.7 billion for the years 2025-2027, respectively [5][11]. - The expected EPS for 2026 is HKD 3.08, with a projected PB ratio of 1.80x [5][11]. - The company anticipates an increase in returns from regulated assets entering a new regulatory period in 2026, which is expected to support future earnings growth [4][11].

Investment Rating - The report maintains a BUY rating for BOE Varitronix, indicating a potential return of over 15% over the next 12 months [1][14]. Core Views - The company is expected to report FY25E revenue of HK$14,533 million, reflecting an 8% year-over-year growth, while net profit is projected to decline by 3% to HK$378 million due to domestic destocking pressure and pricing pressure [1][9]. - For 2H25E, revenue is estimated at HK$7,863 million (+8% YoY) and net profit at HK$198 million (-10% YoY), primarily impacted by domestic demand weakness and profitability in the system segment [1][9]. - Looking ahead to 2026, the report is optimistic about earnings recovery, driven by overseas sales growth, capacity ramp-up in Vietnam, and margin improvements from the Chengdu plant and system business [1][9]. Financial Summary - FY25E revenue is projected at HK$14,533 million, with a year-over-year growth of 8.1%, while net profit is expected to decline by 3.3% to HK$378 million [2][10]. - The report revises down FY25-27E EPS by 5-7% to account for near-term domestic headwinds and pricing pressure [1][12]. - The target price is set at HK$8.40, down from the previous target of HK$8.84, indicating a potential upside of 79.8% from the current price of HK$4.67 [3][14]. Earnings Estimates - The earnings estimates for FY25E include revenue of HK$14,533 million, operating profit of HK$421 million, and net profit of HK$378 million [10][12]. - For FY26E, revenue is expected to grow to HK$15,979 million, with net profit increasing to HK$473 million, reflecting a 25% year-over-year growth [2][11]. - The report highlights a projected operating margin of 2.9% for FY25E, improving to 3.3% by FY26E [12][19]. Valuation Metrics - The stock is currently trading at 7.8x FY26E P/E and 6.3x FY27E P/E, which the report considers attractive in terms of risk/reward [1][14]. - The report emphasizes the company's industry leadership in the auto display market and strong support from its parent company, BOE, for R&D technology and order/client wins [1][14].

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected relative performance increase of over 15% against the benchmark index within the next 6 to 12 months [9] Core Insights - The company has entered into a licensing agreement with Solstice Oncology for the clinical-stage candidate HBM4003 (CTLA-4 antibody), which includes an upfront payment of over $105 million, enhancing the company's cash flow [5] - HBM4003 is the first fully human heavy-chain antibody to enter clinical trials globally, showing strong anti-tumor effects and a differentiated pharmacokinetic profile, with potential applications in various advanced solid tumors [5] - The company forecasts significant revenue growth, projecting total revenues of 1.4 billion, 1.594 billion, and 1.485 billion yuan for 2025, 2026, and 2027 respectively, alongside substantial net profit increases [5][3] Financial Projections - The company anticipates a revenue of 635 million yuan for 2023, followed by a decrease to 274 million yuan in 2024, and a rebound to 1.4 billion yuan in 2025, reflecting a year-on-year growth rate of 411% [3] - Net profit is expected to rise dramatically from 20 million yuan in 2024 to 665 million yuan in 2025, with a projected growth rate of 3,229% [3] - The earnings per share (EPS) is projected to increase from 0.02 yuan in 2024 to 0.74 yuan in 2025, and further to 0.86 yuan in 2026 [3][8] Valuation Metrics - The price-to-earnings (P/E) ratio is expected to decrease from 500.3 in 2024 to 15.0 in 2025, indicating improved valuation as earnings grow [3][8] - The price-to-book (P/B) ratio is projected to decline from 11.2 in 2024 to 4.7 in 2025, reflecting a more favorable valuation as the company matures [3][8]

证券研究报告·海外公司点评·其他金融(HS) 香港交易所（00388.HK） 股价走势 2025 年年报点评：市场交投活跃，IPO 募资 金额全球第一，全年业绩创历史新高 买入（维持） | [盈利预测与估值 Table_EPS] | 2024A | 2025A | 2026E | 2027E | 2028E | | --- | --- | --- | --- | --- | --- | | 营业总收入（百万港元） | 22,374 | 29,161 | 30,582 | 32,734 | 35,332 | | 同比（%） | 9.06% | 30.33% | 4.87% | 7.04% | 7.94% | | 归母净利润（百万港元） | 13,050 | 17,754 | 18,966 | 20,512 | 22,415 | | 同比（%） | 10.02% | 36.05% | 6.83% | 8.15% | 9.28% | | EPS-最新摊薄（港元/股） | 10.29 | 14.00 | 14.96 | 16.18 | 17.68 | | P/E（现价&最新摊薄） | 40.36 | 29.66 | ...

Investment Rating - The report maintains an "Outperform" rating for BeiGene [2][14]. Core Insights - In FY25, BeiGene achieved revenue of USD 5.34 billion, representing a 40% year-over-year increase, with product revenue of USD 5.28 billion, slightly exceeding management's guidance [3][11]. - The net profit attributable to the parent company was USD 0.29 billion, a turnaround from a loss of USD 0.64 billion in FY24, indicating a successful operational recovery [3][11]. - Management projects FY26 revenue to be between USD 6.2 billion and USD 6.4 billion, with GAAP operating profit expected to be between USD 0.7 billion and USD 0.8 billion [3][11]. Financial Summary - Revenue growth is forecasted at 55% for FY25, 40% for FY26, and 20% for FY27 [9]. - Net profit is expected to grow significantly, with projections of USD 0.61 billion for FY26 and USD 1.04 billion for FY27, reflecting a 113% and 70% increase respectively [9][14]. - Gross profit margin is projected to remain strong at around 87.5% for FY26 and FY27 [9]. Sales Performance - Zanubrutinib generated full-year revenue of USD 3.93 billion, up 49% year-over-year, with significant contributions from the U.S. market [12]. - Tislelizumab achieved revenue of USD 0.74 billion, marking a 19% increase year-over-year [13]. - Collaboration product sales in China reached USD 0.62 billion, driven by growth in specific drugs [13]. Future Catalysts - Key catalysts for 1H26 include the approval of Sonrotoclax for R/R MCL and interim analysis of zanubrutinib in 1L MCL [16]. - In 2H26, significant events include the submission for accelerated approval of BTK CDAC and the initiation of a Phase 3 trial for Sonrotoclax in combination therapy for multiple myeloma [16].

Investment Rating - The report maintains a "Buy" rating for the company, indicating a strong expectation of performance relative to the market [1]. Core Insights - The company's profit forecast for 2025 exceeds expectations, with projected net profits ranging from 680 million to 820 million RMB, representing a year-on-year increase of 647% to 801% [6]. - The significant increase in net profit is attributed to higher battery sales, increased investment income from joint ventures, improved product yield and capacity utilization through AI-driven algorithms, and effective cost control measures leading to higher gross margins [6]. - The company is expected to benefit from a favorable market environment for electric vehicles (EVs) and energy storage, with the lithium battery market projected to see a 30% year-on-year increase in total shipments by 2026 [6]. Financial Data and Profit Forecast - Revenue projections for the company are as follows: - 2023: 4,162 million RMB - 2024: 5,130 million RMB - 2025: 8,341 million RMB - 2026: 12,981 million RMB - 2027: 18,041 million RMB - Year-on-year growth rates for revenue are projected at 26.48% for 2023, 23.28% for 2024, 62.57% for 2025, 55.64% for 2026, and 38.98% for 2027 [5][7]. - The net profit attributable to ordinary shareholders is expected to be: - 2023: -590 million RMB - 2024: 91 million RMB - 2025: 733 million RMB - 2026: 1,297 million RMB - 2027: 1,897 million RMB - The projected earnings per share (EPS) are -0.31 RMB for 2023, 0.04 RMB for 2024, 0.29 RMB for 2025, 0.51 RMB for 2026, and 0.74 RMB for 2027 [5][7].